IDXXIdexx Laboratories
$675.90+7.5% 1Y
$675.90
$504.5952 weeks$766.68
The business
How IDXX's business earns
Idexx Laboratories earns 49% on the capital it employs against an estimated 9.0% cost of capital.
49%
Return on invested capital · cost of capital 9.0% · 40 points above the estimated cost of capital
- Operating margin
- 32%
Operating margin · Diagnostics & Research median 7.1% · 12 months to Sep 30, 2026
- Cash conversion
- 1.18×
Cash conversion · 1.03× a year ago · operating cash flow divided by operating profit after tax
- Share count, year on year
- −2.0%
Share count, year on year · fewer shares than a year ago
Operating margin by fiscal year
| Year | Operating margin |
|---|---|
| FY2020 | 26% |
| FY2021 | 29% |
| FY2022 | 27% |
| FY2023 | 30% |
| FY2024 | 29% |
| FY2025 | 32% |
Details›
- Gross margin12 months to Sep 30, 2026
- 63%
- Operating margin12 months to Sep 30, 2026
- 32%
- Net margin12 months to Sep 30, 2026
- 25%
- Free cash flow margin
- 28%
- R&D as % of revenue
- 5.7%
- Revenue, trailing twelve months
- $4.66B
- Free cash flow, trailing twelve months
- $1.30B
- Net income, trailing twelve months
- $1.18B
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 49%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Diagnostics & Research
The closest names by size in the same industry